2014
Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Lewis K, Sekulic A, Hauschild A, Migden M, Oro A, LoRusso P, Rudin C, Dirix L, Solomon J, Hainsworth J, Williams S, Hou J, Von Hoff D. Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies. Journal Of Clinical Oncology 2014, 32: 9012-9012. DOI: 10.1200/jco.2014.32.15_suppl.9012.Peer-Reviewed Original Research
2012
1111PD Expanded Access Study of Advanced Bcc Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib
Weiss G, Oro A, Chang A, Solomon J, LoRusso P, Hamid O, Chen D, McKenna E, Feng S, Hainsworth J. 1111PD Expanded Access Study of Advanced Bcc Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib. Annals Of Oncology 2012, 23: ix362. DOI: 10.1016/s0923-7534(20)33683-8.Peer-Reviewed Original ResearchAdverse eventsClinical activitySafety profileDisease progressionSpeakers bureauAdvanced basal cell carcinomaInvestigator-assessed response ratePivotal phase II studiesSeverity of AEsTreatment-emergent adverse eventsHedgehog pathway inhibitor vismodegibAccess StudyAdvanced BCC patientsPathogenesis of BCCRECIST measurable diseaseMedian disease durationPhase II studySerious adverse eventsSignificant clinical activityAcceptable safety profileEffective treatment optionBasal cell carcinomaClass small-molecule inhibitorEvaluable patientsStable disease